Literature DB >> 31737509

Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?

Andrew J Piper1, Kartik Sehgal1, Daniel B Costa1, Deepa Rangachari1.   

Abstract

Entities:  

Year:  2019        PMID： 31737509      PMCID： PMC6835108          DOI： 10.21037/tlcr.2019.05.12

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  29 in total

1.  Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.

Authors:  Gregory P Kalemkerian; Navneet Narula; Erin B Kennedy; William A Biermann; Jessica Donington; Natasha B Leighl; Madelyn Lew; James Pantelas; Suresh S Ramalingam; Martin Reck; Anjali Saqi; Michael Simoff; Navneet Singh; Baskaran Sundaram
Journal:  J Clin Oncol       Date:  2018-02-05       Impact factor: 44.544

2.  Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.

Authors:  Luis Paz-Ares; Alexander Luft; David Vicente; Ali Tafreshi; Mahmut Gümüş; Julien Mazières; Barbara Hermes; Filiz Çay Şenler; Tibor Csőszi; Andrea Fülöp; Jerónimo Rodríguez-Cid; Jonathan Wilson; Shunichi Sugawara; Terufumi Kato; Ki Hyeong Lee; Ying Cheng; Silvia Novello; Balazs Halmos; Xiaodong Li; Gregory M Lubiniecki; Bilal Piperdi; Dariusz M Kowalski
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

3.  EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

Authors:  Justin F Gainor; Alice T Shaw; Lecia V Sequist; Xiujun Fu; Christopher G Azzoli; Zofia Piotrowska; Tiffany G Huynh; Ling Zhao; Linnea Fulton; Katherine R Schultz; Emily Howe; Anna F Farago; Ryan J Sullivan; James R Stone; Subba Digumarthy; Teresa Moran; Aaron N Hata; Yukako Yagi; Beow Y Yeap; Jeffrey A Engelman; Mari Mino-Kenudson
Journal:  Clin Cancer Res       Date:  2016-05-25       Impact factor: 12.531

4.  Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer.

Authors:  Lorena Ostios-Garcia; Jennifer Faig; Giulia C Leonardi; Anika E Adeni; Safiya J Subegdjo; Christine A Lydon; Deepa Rangachari; Mark S Huberman; Kartik Sehgal; Meghan Shea; Paul A VanderLaan; Matthew P Cheng; Francisco M Marty; Sarah P Hammond; Daniel B Costa; Mark M Awad
Journal:  J Thorac Oncol       Date:  2018-04-06       Impact factor: 15.609

5.  Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer.

Authors:  Jose M Pacheco; Dexiang Gao; Derek Smith; Thomas Purcell; Mark Hancock; Paul Bunn; Tyler Robin; Arthur Liu; Sana Karam; Laurie Gaspar; Brian Kavanagh; Chad Rusthoven; Dara Aisner; Robert Doebele; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2018-12-30       Impact factor: 15.609

6.  Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.

Authors:  Giulia C Leonardi; Justin F Gainor; Mehmet Altan; Sasha Kravets; Suzanne E Dahlberg; Lydia Gedmintas; Roxana Azimi; Hira Rizvi; Jonathan W Riess; Matthew D Hellmann; Mark M Awad
Journal:  J Clin Oncol       Date:  2018-05-10       Impact factor: 44.544

7.  Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review.

Authors:  Michael R Cook; Chul Kim
Journal:  JAMA Oncol       Date:  2019-07-01       Impact factor: 31.777

8.  Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib.

Authors:  A J Schoenfeld; K C Arbour; H Rizvi; A N Iqbal; S M Gadgeel; J Girshman; M G Kris; G J Riely; H A Yu; M D Hellmann
Journal:  Ann Oncol       Date:  2019-05-01       Impact factor: 32.976

Review 9.  A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC.

Authors:  Juliet A Carmichael; Daisy Wing-San Mak; Mary O'Brien
Journal:  Cancers (Basel)       Date:  2018-07-18       Impact factor: 6.639

Review 10.  Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC).

Authors:  Irene Moya-Horno; Santiago Viteri; Niki Karachaliou; Rafael Rosell
Journal:  Ther Adv Med Oncol       Date:  2018-01-09       Impact factor: 8.168
View more
  4 in total

1.  Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy.

Authors:  Yanjun Xu; Hui Li; Zhiyu Huang; Kaiyan Chen; Xiaoqing Yu; Jiamin Sheng; Han-Han Zhang; Yun Fan
Journal:  Transl Lung Cancer Res       Date:  2020-12

2.  Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.

Authors:  Kartik Sehgal; Ritu R Gill; Page Widick; Poorva Bindal; Danielle C McDonald; Meghan Shea; Deepa Rangachari; Daniel B Costa
Journal:  JAMA Netw Open       Date:  2021-02-01

Review 3.  Imperfect Predictors for Lung Cancer Immunotherapy-A Field for Further Research.

Authors:  Kamila Wojas-Krawczyk; Tomasz Kubiatowski
Journal:  Front Oncol       Date:  2020-11-30       Impact factor: 6.244

4.  Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer.

Authors:  Kartik Sehgal; Anushi Bulumulle; Heather Brody; Ritu R Gill; Shravanti Macherla; Aleksandra Qilleri; Danielle C McDonald; Cynthia R Cherry; Meghan Shea; Mark S Huberman; Paul A VanderLaan; Glen J Weiss; Paul R Walker; Daniel B Costa; Deepa Rangachari
Journal:  Clin Lung Cancer       Date:  2020-06-05       Impact factor: 4.785
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.